



EMvision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au

EMVISION APPOINTS HEAD OF QUALITY & REGULATORY AFFAIRS

EMvision Medical Devices Limited (ASX: EMV) ("EMvision" or the "Company") is pleased to announce that it has strengthened its organisational capability with the appointment of medical device quality and regulatory expert. Ruth Cremin, in the role of Head of Quality and Regulatory Affairs for EMvision.

Ms Cremin was previously Head of Quality and Regulatory Affairs at Nanosonics (ASX:NAN). Prior to Nanosonics, Ruth was a Senior Regulatory Affairs Specialist at Cochlear (ASX:COH) and Quality and Regulatory Officer at Pfizer (NYSE:PFE).

Ms Cremin has been responsible for multiple successful medical device registrations and approvals, including FDA and CE mark clearance for the most recent version of Nanosonics' Trophon. Ms Cremin was responsible for developing and driving the global regulatory strategy for Nanosonics for 8 years and for Cochlear's implant systems and accessories in Asia Pacific. Her experience spans global markets including Australia, USA, Canada, Europe, Japan, South Korea, China and other countries in Asia.

Ms Cremin will bring over 18 years experience in international Regulatory Affairs and Quality Assurance to EMvision, and will lead and drive the execution of the Company's global regulatory strategy and quality oversight for its medical imaging devices.

CEO Dr Ron Weinberger said; "I have worked with Ruth for many years and she is an exceptional professional. Her extensive experience in Quality and Regulatory Affairs for medical devices will contribute significantly to EMV's go-to-market strategy.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills Investor & Media Relations +61 468 385 208 michael@spring-communications.com.au Scott Kirkland Executive Director +61 2 8667 5337 skirkland@emvision.com.au

About EMvision Medical Devices

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMvision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.7 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.